Literature DB >> 8826850

High levels of loss at the 17p telomere suggest the close proximity of a tumour suppressor.

G R White1, M Stack, M Santibáñez-Koref, D S Liscia, T Venesio, J C Wang, C Helms, H Donis-Keller, D C Betticher, H J Altermatt, P R Hoban, J Heighway.   

Abstract

High levels of loss of distal markers on 17p13.3 in breast cancer suggested the presence within the region of at least one tumour-suppressor gene. Here we describe the derivation of two biallelic polymorphisms from the 17p telomeric yeast artificial chromosome (YAC) TYAC98. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and multiplex PCR analysis demonstrated that the high level of allelic imbalance observed in breast tumours represented loss of constitutional heterozygosity (LOH) and that this LOH extended to the telomere. Lung carcinoma (but not Wilms' tumour)-derived DNA again revealed a high level of loss of subtelomeric 17p sequences. Telomeric microsatellite polymorphisms from other chromosome arms did not show such elevated loss in either tumour type. This suggested that the 17p loss observed did not reflect a general telomeric instability and provided further evidence for the presence of a breast cancer tumour-suppressor gene in the distal region of 17p13.3.

Entities:  

Mesh:

Year:  1996        PMID: 8826850      PMCID: PMC2074733          DOI: 10.1038/bjc.1996.449

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Identification of a second pseudoautosomal region near the Xq and Yq telomeres.

Authors:  D Freije; C Helms; M S Watson; H Donis-Keller
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

2.  A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clones.

Authors:  J Riley; R Butler; D Ogilvie; R Finniear; D Jenner; S Powell; R Anand; J C Smith; A F Markham
Journal:  Nucleic Acids Res       Date:  1990-05-25       Impact factor: 16.971

Review 3.  The retinoblastoma gene and cell growth control.

Authors:  R A Weinberg
Journal:  Trends Biochem Sci       Date:  1990-05       Impact factor: 13.807

4.  Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours.

Authors:  J Prosser; A M Thompson; G Cranston; H J Evans
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

5.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

Authors:  K M Call; T Glaser; C Y Ito; A J Buckler; J Pelletier; D A Haber; E A Rose; A Kral; H Yeger; W H Lewis
Journal:  Cell       Date:  1990-02-09       Impact factor: 41.582

6.  p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Authors:  T Mitsudomi; S M Steinberg; M M Nau; D Carbone; D D'Amico; S Bodner; H K Oie; R I Linnoila; J L Mulshine; J D Minna
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

7.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

8.  Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis.

Authors:  C Coles; A M Thompson; P A Elder; B B Cohen; I M Mackenzie; G Cranston; U Chetty; J Mackay; M Macdonald; Y Nakamura
Journal:  Lancet       Date:  1990-09-29       Impact factor: 79.321

9.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

10.  Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer.

Authors:  D C Betticher; J Heighway; P S Hasleton; H J Altermatt; W D Ryder; T Cerny; N Thatcher
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more
  6 in total

1.  Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up.

Authors:  A M Thompson; D N Crichton; R A Elton; M F Clay; U Chetty; C M Steel
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

2.  Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays.

Authors:  Maria Argos; Muhammad G Kibriya; Farzana Jasmine; Olufunmilayo I Olopade; Tao Su; Hanina Hibshoosh; Habibul Ahsan
Journal:  Cancer Genet Cytogenet       Date:  2008-04-15

3.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions.

Authors:  Brian J Miller; Daolong Wang; Ralf Krahe; Fred A Wright
Journal:  Am J Hum Genet       Date:  2003-09-16       Impact factor: 11.025

4.  Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene.

Authors:  D S Liscia; R Morizio; T Venesio; C Palenzona; M Donadio; R Callahan
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

5.  Three new regions on chromosome 17p13.3 distal to p53 with possible tumor suppressor gene involvement in lung cancer.

Authors:  E Tsuchiya; A Tanigami; Y Ishikawa; K Nishida; M Hayashi; Y Tokuchi; T Hashimoto; S Okumura; S Tsuchiya; K Nakagawa
Journal:  Jpn J Cancer Res       Date:  2000-06

6.  Different behaviour of DVL1, DVL2, DVL3 in astrocytoma malignancy grades and their association to TCF1 and LEF1 upregulation.

Authors:  Anja Kafka; Mateja Bačić; Davor Tomas; Kamelija Žarković; Anja Bukovac; Niko Njirić; Goran Mrak; Željka Krsnik; Nives Pećina-Šlaus
Journal:  J Cell Mol Med       Date:  2018-11-23       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.